IPP Bureau
Biocon Biologics partners Adagio to manufacture antibody for COVID-19
By IPP Bureau - July 27, 2021
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Panacea Biotec posts consolidated loss of Rs. 57.35 Cr in Q1FY22
By IPP Bureau - July 26, 2021
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
Glenmark Life Sciences IPO to open on July 27, 2021
By IPP Bureau - July 26, 2021
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Lonza reports strong momentum in H1 2021
By IPP Bureau - July 24, 2021
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
By IPP Bureau - July 23, 2021
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
By IPP Bureau - July 22, 2021
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Syngene Q1 FY22 revenue grows 41%
By IPP Bureau - July 21, 2021
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
EMA grants ODD to Saroglitazar Mg
By IPP Bureau - July 21, 2021
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Granules clears US FDA audit
By IPP Bureau - July 21, 2021
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
Celanese opens drug delivery feasibility lab at Florence, Kentucky site
By IPP Bureau - July 21, 2021
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Balaxi Pharmaceuticals Q1 revenue increases by 12%
By IPP Bureau - July 20, 2021
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Merck invests €270 million in a new research center at Darmstadt
By IPP Bureau - July 19, 2021
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Lonza extends collaboration with Biopharma company
By IPP Bureau - July 19, 2021
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Veeda Clinical Research acquires majority stake in Bioneeds
By IPP Bureau - July 18, 2021
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Cadila Healthcare completes sale of animal healthcare business
By IPP Bureau - July 16, 2021
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
